A Belgian multicentre study of fluvoxamine in depressive outpatients
peer reviewed ; Fluvoxamine, a new antidepressant that specifically inhibits serotonin reuptake, was studied in 272 outpatients in a six-week multicentre trial in Belgium. On the Hamilton Depression Scale, the mean score dropped from 25.2 to 8 after six weeks (p<0.00001). The Clinical Global Impression scores showed similar evolution. Fluvoxamine is a real antidepressant with a marked effect on mood. Its effective dosage is 100 mg to 200 mg/day. Its tolerance, notably at the cardiovascular level, is excellent.
Verfasser: | |
---|---|
Dokumenttyp: | journal article |
Erscheinungsdatum: | 1985 |
Verlag/Hrsg.: |
Acta Medica Belgica
|
Schlagwörter: | Adult / Ambulatory Care / Antidepressive Agents / Depressive Disorder / Female / Fluvoxamine / Humans / Male / Oximes / Psychiatric Status Rating Scales / Social & behavioral sciences / psychology / Treatment & clinical psychology / Sciences sociales & comportementales / psychologie / Traitement & psychologie clinique |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26513949 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://orbi.uliege.be/handle/2268/259754 |